Kyowa Hakko Kirin Starts Phase II For Adult T-cell Lymphoma Antibody Drug
This article was originally published in PharmAsia News
Executive Summary
Kyowa Hakko Kirin commenced a Japanese domestic Phase II trial to confirm safety and efficacy for KW-0761 to treat adult patients with CCR4-positive T-cell lymphoma